DI-B4

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDI-B4
Drug Alias NameAnti-CD19 monoclonal antibody - Merck KGaADI-B4
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck SeronoCancer Research UK
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck SeronoCancer Research UK
Active IndicationsN/A
Inactive IndicationsWaldenstrom MacroglobulinemiaLymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A